Factor VIII Deficiency Treatment Market (1)
                     Rest of the World Factor VIII Deficiency Treatment Market- Size, Share, Outlook, 
and Opportunity Analysis, 2019 - 2027   
Novel product launches by the market players in the factor VIII deficiency treatment is 
expected to boost growth of the market over the forecast period. For instance, in June 
2019, Novo Nordisk received marketing authorization from European commission for 
Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, 
indicated for surgical procedures in adolescents and adults with hemophilia A 
(congenital factor VIII deficiency). 
Request a sample copy of this report:- 
https://www.coherentmarketinsights.com/insight/request-sample/3257 
Novel product launches by the market players in the factor VIII deficiency treatment is
expected to boost growth of the market over the forecast period. For instance, in June
2019, Novo Nordisk received marketing authorization from European commission for
Esperoct  in  Europe.  Esperoct  is  the  brand name for  turoctocog  alfa  pegol,  N8-GP,
indicated  for  surgical  procedures  in  adolescents  and  adults  with  hemophilia  A
(congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt Ltd
launched hemophilia A drug emicizumab, branded as Hemlibra in India. It is indicated
for prophylactic treatment for reducing frequency of bleeding episodes in patients with
hemophilia A, through Factor VIII inhibitors.
Furthermore, increasing government initiatives to promote awareness about hemophilia
treatment  among  population  is  expected  to  propel  growth  of  the  market  over  the
forecast period. For instance, the National Bleeding Authority (NBA) provides funding to
AHCDO  (Australian  Hemophilia  Center  Directors’  Organization)  for  treatment  and
management hemophilia A.  to support the effective management of hemophilia (Factor
VIII Deficiency) in Australia.
The rest of the world factor VIII deficiency treatment market is expected to exhibit a
CAGR of 4.7% over the forecast period (2019-2027).
Rising cases of bleeding disorders is expected to boost growth of the rest of the world
factor VIII deficiency treatment market
The rest  of  the world  factor VIII  deficiency treatment market  is expected to  witness
significant  growth,  owing  to  rising  cases  of  hemophilia  or  bleeding  disorders.  For
instance,  according to  the  Australian  Bleeding Disorders Registry  2016 statistics,  in
2015 there were around 4,941 patients, who suffered from common hereditary bleeding
disorders, of which 2,301 patients were diagnosed with hemophilia A, and 548 patients
were  diagnosed  with  hemophilia  B  in  Australia.  Thus,  increasing  prevalence  of
hemophilia in Australia is expected to drive demand for factor VIII deficiency treatment
over  the  forecast  period.  Moreover,  increasing  demand for  efficient  therapeutics  for
treatment of factor VIII deficiency from emerging economies such as India is expected
to drive the market growth over the forecast period. For instance, according to the World
Federation  of  Hemophilia,  2017  statistics,  in  India,  around  18,353  people  were
diagnosed with hemophilia in 2016.
Increasing healthcare expenditure and reimbursement policies in respective countries or
regions are expected to drive the market growth
Latin America is expected to hold dominant position in the rest of the world factor VIII
deficiency treatment market, owing to increasing per capita healthcare spending in Latin
America, which is expected to drive the market growth in the region over the forecast
period.  For  instance,  according  to  the  World  Bank  estimates,  2017,  per  capita
healthcare expenditure increased significantly across Latin America during the six-year
(2008-2014)  interval,  with  an  increase of  31% in  Brazil,  54% in  Chile,  and 58% in
Columbia.
Moreover, Asia Pacific is expected to be the second largest dominating region in the
rest  of  the  world  factor  VIII  deficiency  treatment  market,  owing  to  rising  favorable
reimbursement policies for hemophilia treatment in economies such as China, which is
expected to drive the Asia Pacific market growth. For instance, according to the Chinese
Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by
health insurance schemes in over 80% of the cities in China, with reimbursement caps
and patient co-pay requirements over 50%. Moreover, annual reimbursement is usually
accounted below US$ 16,000.
Major players operating in the rest of the world factor VIII deficiency treatment market
include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F.
Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.
Get the main link:-  https://www.coherentmarketinsights.com/market-insight/rest-of-the-world-
factor-viii-deficiency-treatment-market-3257 
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/